Aurora Cannabis (TSE:ACB) has acquired Safari Flower Company for $26.5 million, adding an EU GMP certified cultivation facility to its network. This acquisition aims to expand Aurora's EU GMP capacity for international medical markets and is expected to contribute positively to Adjusted EBITDA from fiscal 2027. The deal strengthens Aurora's position in high-margin global medical cannabis markets and supports its strategy to capture greater international market share.

Citigroup downgraded EQT (NYSE:EQT) from a "strong-buy" to a "hold" rating, as reported by Zacks.com. This comes amidst varied analyst opinions, with several firms reiterating "buy" or "outperform" ratings and target price adjustments. The article also details EQT's recent stock performance, earnings, insider transactions, and institutional investor activity, alongside key news impacting the company.

Zacks Research has upgraded Arista Networks (NYSE:ANET) from a "hold" to a "strong-buy" rating. This upgrade is supported by other analysts who have also issued "overweight" or "buy" ratings with price targets ranging from $165.00 to $200.00. The company's recent strong earnings performance and its pivotal role in AI infrastructure are highlighted as key drivers for this positive outlook.

HC Wainwright & Co. has reiterated a Buy rating for Incyte (INCY), maintaining a price target of $135.00, signaling confidence in the biopharmaceutical company's growth potential. GuruFocus assesses INCY as 1.1% undervalued with a strong GF Score™ of 93/100, driven by exceptional financial strength and profitability. Despite recent insider selling, the stock presents a solid investment opportunity due to its undervaluation and robust financials.

Prairiewood Capital LLC increased its stake in Ares Capital Corporation (NASDAQ:ARCC) by 22.9% in the 4th quarter, purchasing an additional 56,465 shares, bringing its total holdings to 303,282 shares valued at $6.135 million. The article also details other institutional investor activity, Ares Capital's stock performance, recent earnings, dividend announcement, and insider trading by company executives. Analyst ratings for ARCC are mixed, with an average "Moderate Buy" rating and a price target of $21.38.

UnitedHealth (UNH) exemplifies the "Dogs of the Dow" strategy due to its significant stock price decline and rising dividend yield, making it an attractive contrarian investment. Despite recent challenges, management and Wall Street analysts are confident in a turnaround, supported by strong 2026 guidance and insider buying. However, risks such as a high medical care ratio and declining membership persist, alongside potential legal actions.

Zacks Research has significantly raised its near-term earnings estimates for Antero Resources (AR), boosting Q3 2026 EPS to $0.88 and full-year 2026 EPS to $3.43, alongside upward revisions for several 2026/2027 quarters. This optimistic outlook follows Antero's recent beat on quarterly expectations and has led several other firms to raise their price targets and ratings, contributing to a "Moderate Buy" consensus. The stock currently trades around $36.12 with a P/E of 17.88 and a market capitalization of approximately $11.1 billion.

This article details top Wall Street analyst research calls for Wednesday, April 15, 2026, including upgrades, downgrades, and new initiations for various companies like American Tower, SolarEdge Technologies, Align Technology, and Autodesk. It also provides a market recap, highlighting positive movements in stocks, gold, and cryptocurrencies, alongside declines in treasury yields and oil prices. The market's positive sentiment was attributed to improving inflation data and geopolitical factors.

Philip Morris International (PMI) will host a live audio webcast on Wednesday, April 22, 2026, at 9:00 a.m. ET to discuss its 2026 First-Quarter financial results, which will be released at approximately 7:00 a.m. ET the same day. The webcast will feature Emmanuel Babeau, Group CFO, discussing financial results and holding a Q&A session with investors. PMI, a global consumer goods company, is focused on a smoke-free future, with smoke-free products accounting for 41.5% of its 2025 net revenues.

Achieve Life Sciences has completed the transfer of cytisinicline manufacturing to Adare Pharma Solutions in Vandalia, Ohio, establishing U.S.-based production and supply-chain redundancy. This move comes after a third-party manufacturing facility received an Official Action Indicated (OAI) classification from the FDA. Achieve expects a Complete Response Letter by June 20, 2026, plans to resubmit its New Drug Application naming Adare in Q4 2026, and anticipates a commercial launch in the first half of 2027.